Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy

Last updated: July 20, 2012
Sponsor: Heidelberg University
Overall Status: Completed

Phase

3

Condition

Intra-abdominal Infections

Gall Bladder Disorders

Liver Disease

Treatment

N/A

Clinical Study ID

NCT00447304
2006-002056-14
AC-DC-01/Version 02/6.04.06
  • Ages > 18
  • All Genders

Study Summary

Acute cholecystitis is frequent in the elderly, or in patients with gall stones. Most cases of severe or recurrent cholecystitis need surgery as final therapy. Today, the performed procedure in most cases for cholecystectomy in the western world is laparoscopic cholecystectomy. Only in some cases an open surgery has to be performed. Unclear is, what time point is best, concerning outcome and morbidity of the patient, immediate surgery or initial conservative therapy using antibiotics and symptomatic therapy with cholecystectomy later on. Today the performed procedure is mainly chosen by the fact, what doctor sees the patient first, surgeon or gastroenterologist. This study is performed to evaluate if one therapy is superior.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients of age > 18 years

  • Patients with acute cholecystitis based on three of the following signs

  • abdominal pain in the upper right quadrant

  • Murphy's sign

  • leucocytosis > 10 /ml

  • rectal temperature > 38 °C or < 36.5 °C plus

  • cholecystolithiasis (stones / sludge) or sonographic signs of cholecystitis (thickening and triple layer formation of the gall bladder wall)

  • Immediate antibiotic therapy (400 mg Moxifloxacin i.v. once a day)

  • Laparoscopic cholecystectomy possible within 24 hours after presentation of thepatient

  • Informed consent

Exclusion

Exclusion Criteria:

  • ASA IV and V (table 2)

  • Septic shock

  • Perforation or abscess of the gall bladder

  • Impossibility of laparoscopic surgery (further surgery, surgeon, …)

  • Additional need of antibiotics due to secondary disease

  • Known intolerability of Moxifloxacin

  • Known or possible pregnancy, breast feeding

  • Life-threatening diseases (life-expectancy < 48 hours)

  • End-stage liver disease (Child-Pugh C)

  • Psychiatric or severe neurologic disease

  • Relevant bradycardia or other symptomatic arrhythmias

  • Significant cardiac disease

  • Known long QT-disorders

  • Electrolyte disorders, especially hypocalcemia

  • Known intolerability of chinolones

  • Earlier participation in this trial

Study Design

Total Participants: 644
Study Start date:
October 01, 2006
Estimated Completion Date:
December 31, 2010

Connect with a study center

  • University Hospital Heidelberg

    Heidelberg, 69120
    Germany

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.